Can You Prescribe Ubrelvy with Prozac and Hydroxyzine?
Yes, you can safely prescribe ubrogepant (Ubrelvy) with fluoxetine (Prozac) and hydroxyzine—there are no contraindications or clinically significant drug interactions between these medications.
Drug Interaction Analysis
Fluoxetine (Prozac) with Ubrelvy
Fluoxetine is a weak CYP3A4 inhibitor and a moderate CYP2D6 inhibitor. According to the FDA label for ubrogepant, weak CYP3A4 inhibitors are predicted to increase ubrogepant exposure by no more than 2-fold 1. This modest increase is not clinically significant and does not require dose adjustment.
The FDA label specifically states that ubrogepant was studied with various medications and found to have no significant pharmacokinetic interactions with multiple drug classes 1. While fluoxetine is not specifically listed in the interaction studies, its weak CYP3A4 inhibition falls well below the threshold requiring dose modification.
Hydroxyzine with Ubrelvy
Hydroxyzine has no significant interaction with ubrogepant. Hydroxyzine is primarily metabolized by CYP2D6 and does not meaningfully affect CYP3A4 activity. The FDA label confirms that ubrogepant is not an inhibitor of CYP2D6 and only acts as a weak inhibitor at concentrations not expected to be clinically significant 1.
Dosing Recommendations
- Standard ubrogepant dosing applies: 50 mg or 100 mg orally at migraine onset
- A second dose may be taken at least 2 hours after the initial dose if needed (maximum 200 mg/24 hours)
- No dose adjustment required for concomitant use with fluoxetine or hydroxyzine 1
Clinical Context
According to the 2025 American College of Physicians guidelines, ubrogepant (a CGRP antagonist-gepant) should be considered for moderate to severe acute episodic migraine in patients who do not tolerate or have inadequate response to combination therapy of a triptan with an NSAID or acetaminophen 2. The combination with fluoxetine and hydroxyzine does not alter this recommendation.
Important Caveats
Avoid these actual contraindications with ubrogepant:
- Strong CYP3A4 inhibitors (ketoconazole, clarithromycin, itraconazole) are absolutely contraindicated 1
- Moderate CYP3A4 inhibitors (verapamil, cyclosporine, ciprofloxacin, fluconazole) require dose reduction to 50 mg with no second dose within 24 hours 1
Monitor for:
- Medication overuse headache (threshold: ≥10 days/month for gepants, similar to triptans) 2
- Hypertension (can develop or worsen with ubrogepant) 1
- Raynaud's phenomenon (rare but reported) 1
The safety profile of ubrogepant has been well-established in long-term studies with over 31,000 doses administered, showing good tolerability with treatment-related adverse events in only 10-11% of patients 3.